Saruparib

Saruparib (AZD5305) is a small-molecule drug developed by AstraZeneca. Its target is PARP (the sponsor names PARP (poly(ADP-ribose) polymerase)). The sponsor states: Saruparib (AZD5305) is an oral PARP inhibitor, studied added to androgen deprivation therapy (with or without abiraterone) in patients with BRCA-mutated prostate cancer. It is the investigational product in 4 recruiting or active industry-led phase 2 and phase 3 interventional cancer trials, including phase 3 studies NCT06952803 (A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation) and NCT06120491 (Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents), in prostate cancer, ovarian cancer, non-small-cell lung cancer and endometrial cancer. The largest, NCT06120491, plans to enrol 1898 participants (actual) with primary completion expected 2027-09-30. Status reflects the highest phase registered on ClinicalTrials.gov at the 2026-09-11 check; no efficacy results are recorded here.